- Patent Title: RTEF-1 variants and the use thereof for inhibition of angiogenesis
-
Application No.: US15369583Application Date: 2016-12-05
-
Publication No.: US09937269B2Publication Date: 2018-04-10
- Inventor: J. Timothy Stout , Trevor J. McFarland , Binoy Appukuttan
- Applicant: Research Development Foundation
- Applicant Address: US NV Carson City
- Assignee: Research Development Foundation
- Current Assignee: Research Development Foundation
- Current Assignee Address: US NV Carson City
- Agency: Parker Highlander PLLC
- Main IPC: A61K48/00
- IPC: A61K48/00 ; C12N15/11 ; C12N15/85 ; C12N15/86 ; A61K45/06 ; C07K14/435 ; C07K7/06 ; C07K14/47 ; A61K9/00 ; A61K38/10 ; A61K38/17 ; C07K7/08 ; C07K16/00 ; A61K38/00 ; A61K38/16 ; A61N5/10
Abstract:
Dominant negative (DN) variants of transcriptional enhancer factor 1-related (RTEF-1) are described. DN RTEF-1 polypeptides may be directly targeted to cells or delivered in nucleic acid expression vectors to alter cellular transcription. Methods for inhibiting VEGF production and thereby treating angiogenic disorders such as cancer are described. For example, in certain aspects, DN RTEF-1 may be used to treat angiogenic disorders of the eye such as age related macular degeneration (AMD).
Public/Granted literature
- US20170081377A1 RTEF-1 VARIANTS AND THE USE THEREOF FOR INHIBITION OF ANGIOGENESIS Public/Granted day:2017-03-23
Information query
